



CATT

Group Suitability Assessment Group Health Questionnaire

Please return to mwil.hba-ehb@marshmma.com for review.

This Group Health Questionnaire is utilized to assist in the assessment of the risk associated with your group and whether it is a good fit for HBA plan designs.

You acknowledge that you will answer these questions truthfully, completely, following reasonable commercial effort, and to the best of your knowledge. This form may be used and shared with all HBA vendors. This form will also be shared with other vendors outside of HBA that service the plan designs implemented for your group through HBA, including but not limited to insurance and/or reinsurance carriers. To the extent that this form is relied upon by these vendors, false or misleading statements could adversely impact the services provided as well as trigger termination rights. To the extent this form is separately used or analyzed by an insurance company, additional legal or contractual consequences, including, but not limited to, a loss of coverage or denial of coverage may occur.

Legal Name of Group:					
Group Main Address:	_				
SIC#/Industry:	_				
# of Employees current coverage by tier (N/A if			EE + Spouse	EE + Child(ren)	Family
# of Employees to be or coverage:	ffered health		Average Age of offered health c	Employees to be overage:	
HBA Plan Designs being considered:		Essential Value	MVP Bronze M	VIVP Bronze Plus	MVP Silver MVP Gold
TIDA FIAII Designs being	g considered.	MVP Gold-S	MVP Ultra Platinum	MVP Ultra Plati	num-S MVP Ultra HDHF
Requested Effective Da	ate:				
1. I will answer the following reasonable co	eferred to as "any ommercial effort,	one" through	out the rest of this out of my knowledge	questionnaire) tru	uthfully, completely,
Yes, I agree	No		If no, please expl	ain below or in Ai	ppendix as needed.
<u> </u>					
	•	•	ease list the carriers	s/third party adm	inistrators you have
Have you sponsored worked with over the particle.	ast three (3) year No	S.	ease list the carriers	s/third party adm lain below or in A	inistrators you have spendix as needed.
Have you sponsored worked with over the party Yes	nst three (3) year No f eligible participa ontrolled drugs or add an explanati	ants and deper substances (in	If yes, please exp ndents smoke, vapencluding, even if leg	s/third party adm lain below or in A e, or use tobacco gal in your local ju	inistrators you have appendix as needed. products. urisdiction, cannabis
 Have you sponsored worked with over the payers What percentage of the products of the payers 	nst three (3) year No f eligible participa ontrolled drugs or add an explanati	ants and deper substances (in	If yes, please exp ndents smoke, vape ncluding, even if leg ber or percentage on abis products.	s/third party adm lain below or in A e, or use tobacco gal in your local ju of eligible particip	inistrators you have appendix as needed. products. urisdiction, cannabis
 Have you sponsored worked with over the payers What percentage of the products of the payers Does anyone use coproducts of the payers If so, please who use controlled drug 	ast three (3) year No f eligible participa ontrolled drugs or add an explanati gs or substances, No more than five (5)	ants and deper substances (in on of the num including can	If yes, please expendents smoke, vapencluding, even if legber or percentage chabis products. If yes, please exp	s/third party adm lain below or in A e, or use tobacco gal in your local ju of eligible particip lain below or in A	inistrators you have appendix as needed. products. urisdiction, cannabis pants and dependents appendix as needed.



illness; immune system	m disorder; hemophilia; o) years, or does anyone anticipate being treated for a serious cancer; heart disorder/disease; hepatitis C; kidney, organ, or tissue or nervous disorder; substance abuse; or other accident/injury?
Yes	No	If yes, please explain below or in Appendix as needed.
\$10,000 or more in ac or anticipated over th	ccident and/or health or pe e next twelve (12) month nic Diagnosis and High-Co	edical issues such that anyone has incurred or is anticipated to incur prescription drug claims or costs within the last twelve (12) months as? To assist in responding to this question, please see the est Drug listing page. This page is intended to help you accurately
Yes	No	If yes, please explain below or in Appendix as needed.
•	•	ome, disabled, confined in a hospital or treatment facility, nonths to have an upcoming procedure or treatment?
Yes	No	If yes, please explain below or in Appendix as needed.
eligible to participate absence, or Family an	in this health plan? (For ed) d Medical Leave Act ("FN	a dependent? If so, will either the caretaker or the dependent be employees, "disabled" means absent from work, on leave of ALA") benefits due to said employee's medical condition. For orm his or her normal functions of a person of like age.)
Yes	No	If yes, please explain below or in Appendix as needed.
•	n the last six (6) months boutpatient surgical proced	peen advised to have surgery or does anyone anticipate dure?
Yes	No	If yes, please explain below or in Appendix as needed.
		forming or are anticipated over the next twelve (12) months to uties due to illness or injury?
Yes	No	If yes, please explain below or in Appendix as needed.
12. Is anyone now or pregnancy, or carrying		regnant, considered to be at high risk for complications of
Yes	No	If yes, please explain below or in Appendix as needed.
note in the explanation	on both the treatment/mo	ical services related to a worker's compensation claim? If so, please edical services and whether that claim is in dispute or is anticipated ensation claim now or in the next twelve (12) months.

d your upco	oming renewal?	Yes	No	N/A
han +15%?		Yes	No	N/A
olan year		Yes	No	N/A
ewal docun	nents with this GF	IQ.		
_				ie
	For In	ternal Use	e Only	
_				
_	Cov Start	Cov	End	
	Situs State			
_				
<u>-</u>	Date		_	
֡֝֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜	han +15%? plan year newal docur	rewal documents with this GF Following reasonable commercand disclaimers provided in the	han +15%? Plan year Yes Plan year Yes Plan documents with this GHQ. Following reasonable commercial effort, and disclaimers provided in this Group For Internal Use Cov Start Cov	han +15%? Yes No plan year Yes No newal documents with this GHQ. Following reasonable commercial effort, and to the and disclaimers provided in this Group Health For Internal Use Only Cov Start Cov End

Date

Please return to mwil.hba-ehb@marshmma.com for review. No group is authorized for consideration for the HBA Partnership Program without completion of this form by the group and review by HBA.

Broker/Referral Partner - Signature



Health Benefit Alliance Partnership Program

Group Health Questionnaire Appendix

Please use this page to provide more detail to responses in the Group Health Questionnaire which requested further explanation.

	I
Question	Explanation



O30.20-30.209

060.00-60.14

Quadruplet Pregnancy

Preterm Labor

	Potentially Catastrophic	: (ICD-10) Diag
A00-B99	Infectious Disease	P00-P96
B17.1-B17.11	Hepatitis C	P07.00-07.36
C00-D49	Neoplasms	P22.0
C00-C14 C15-C26 C30-C39 C43-C44 C50-C50 C51-C68 C69-C72 C81-C96 D50-D89 D57.1 D61.01 D66 D81.0 D82.1 D83.1 D84.1	Malignancy of oral cavity pharynx Malignant neoplasm of digestive organs Malignant neoplasm of respiratory organs Melanoma Breast Malignancies Genitourinary Malignancies Malignancies of Nervous System Leukemias, Lymphomas and Myelomas Hematologic Disorders Sickle Cell Anemia Aplastic Anemia Hemophilia/Hereditary Factor VIII Deficiency Severe Combined Immune Deficiency (SCID) DiGeorge Syndrome Immune Deficiency T Cells (AIDS) Alpha 1-Antitrypsin	Q00-Q99 Q20-Q28 Q39.0-39.4 Q89.7 S00-T88 S06.0-06.9 S12-S14 S88 T07 T20-T32 T79 T86.00-86.09 T86.90-86.99
E70-E88	Metabolic Disorders	
E75.22 E84.0	Gaucher's Disease	A high good do
G00-G99	Cystic Fibrosis Diseases of the Nervous System	A high-cost drumonthly costs
G12.21	Lou Gehrig's disease (ALS)	monthly costs
G61.0	Guillain-Barre Syndrome	Examples:
G91.1 I00-I99 I27.0 I42.0-I42.9 I46.9 I60.9 J00-J99	Obstructive Hydrocephalus Diseases of Circulatory System Primary Pulmonary Hypertension Cardiomyopathy Cardiac Arrest Subarachnoid Hemorrhage Disease of Respiratory System	Avastin, Iclu Cinryze, Kal Uptravi, Epo Lumizyme, V H.P. Acthar Zaltrap, Hur
J96.00-96.92 K00-K95 K70.0-74.69 K72.00-72.91 N00-N99 N18.1-18.9 O00-O9A	Respiratory Failure Disease of Digestive System Chronic Liver Disease Liver Failure Disease Genitourinary System Chronic Renal Failure Pregnancy, Childbirth & Puerperium	Conditions leadir enzyme deficient Edema, Hunter's Fibrosis, MS, Nep inflammatory con Hemolytic Uremi Pulmonary Arte
030.10-30.109	Triplet Pregnancy	

P00-P96	Perinatal Conditions
P07.00-07.36	Preterm Infant
P22.0	Respiratory Distress Syndrome of Newborn
Q00-Q99	Congenital Malformations
Q20-Q28	Congenital Heart Diseases
Q39.0-39.4	Tracheoesophageal Fistula
Q89.7	Multiple Anomalies
S00-T88	Injury, Poisoning and Trauma
S06.0-06.9	Brain Injuries
S12-S14	Spinal Cord Injuries
S88	Amputations
T07	Multiple Trauma Injuries
T20-T32	Burns
T79	Early Complications of Trauma
T86.00-86.09	Graft vs. Host Disease
T86.90-86.99	Complications of Transplants

High-Cost Drugs

rug is defined as a drug for which s exceed approximately \$10,000.

usig, Taltz, Berinert, Kalbitor, Technivie, alydeco, Tyvaso, Daklinza, Keytruda, oclusa, Kynamro, Entavis, Firazyr, Viekira, Gleevec (imatinib), Opdivo, ar, Orkambi, Yervoy, Harvoni, Soliris, mira, Sovaldi, Zepatier, Ibrance, Stelara

ing to use of high-cost drugs may include: icies (genetic mutations, Hereditary Angio s Syndrome and other), cancers, Cystic phrotic Syndrome, Psoriasis and onditions, Hepatitis C, Hemophilia A,B,C, ia Syndrome, MDS, Narcolepsy and erial Hypertension.